Vistagen Therapeutics Inc (NASDAQ: VTGN) kicked off on Friday, up 12.01% from the previous trading day, before settling in for the closing price of $2.95. Over the past 52 weeks, VTGN has traded in a range of $1.90-$3.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 35.63% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 2.99%. With a float of $27.73 million, this company’s outstanding shares have now reached $29.28 million.
In an organization with 57 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 73.84%, operating margin of -9233.13%, and the pretax margin is -8633.59%.
Vistagen Therapeutics Inc (VTGN) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Vistagen Therapeutics Inc is 9.63%, while institutional ownership is 42.24%.
Vistagen Therapeutics Inc (VTGN) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.42 earnings per share (EPS), lower than consensus estimate (set at -0.38) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.83% during the next five years compared to 35.63% growth over the previous five years of trading.
Vistagen Therapeutics Inc (NASDAQ: VTGN) Trading Performance Indicators
Take a look at Vistagen Therapeutics Inc’s (VTGN) current performance indicators. Last quarter, stock had a quick ratio of 5.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 145.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.58, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.75 in one year’s time.
Technical Analysis of Vistagen Therapeutics Inc (VTGN)
Let’s dig in a bit further. During the last 5-days, its volume was 1.25 million. That was better than the volume of 0.25 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 77.19%.
During the past 100 days, Vistagen Therapeutics Inc’s (VTGN) raw stochastic average was set at 97.24%, which indicates a significant increase from 93.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.24 in the past 14 days, which was higher than the 0.17 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.51, while its 200-day Moving Average is $2.61. However, in the short run, Vistagen Therapeutics Inc’s stock first resistance to watch stands at $3.46. Second resistance stands at $3.60. The third major resistance level sits at $3.86. If the price goes on to break the first support level at $3.06, it is likely to go to the next support level at $2.80. The third support level lies at $2.66 if the price breaches the second support level.
Vistagen Therapeutics Inc (NASDAQ: VTGN) Key Stats
The company with the Market Capitalisation of 101.55 million has total of 30,680K Shares Outstanding. Its annual sales at the moment are 490 K in contrast with the sum of -51,420 K annual income. Company’s last quarter sales were recorded 240 K and last quarter income was -15,100 K.
